Session 4: What should we do for poor responders after chemoradiotherapy: bad biology or should the fight go on?
Where this comes from
- Record sourced from PubMed, PMID 29878687.
- Also identified by DOI 10.1111/codi.14088.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Just over 50% of patients with advanced rectal cancer have a poor response to chemoradiotherapy with resultant poor outcomes. Professor Glimelius reviews the evidence base for defining such patients and the potential role, if any, of further treatment.
Medical subject headings
- Chemoradiotherapy
- Neoadjuvant Therapy
- Rectal Neoplasms